CAMP and prostate carcinoma: For example, a rise in the expression of the CAMP gene and levels of LL-37 secretion are associated with the progression of lung adenocarcinoma, breast, pancreatic and prostate cancers, ovarian cancer, melanoma and squamous cell skin cancer, wherein LL-37, through the CXCR4 receptor, stimulates the migration of breast cancer cells [26].